Melior Discovery Explained

Melior Discovery
Type:Private company
Foundation:2005
Founder:Andrew Reaume
Michael Saporito
Location:Exton, Pennsylvania
Industry:Biotechnology
Products:Pharmaceuticals, contract research

Melior Discovery, Inc. is a private biopharmaceutical company based in Exton, Pennsylvania, USA.

Products and services

The company specializes in drug repositioning and has established a proprietary phenotypic screening platform that it uses for this purpose. Melior also offers certain contract research organization (CRO) services comprising animal models representing different disease conditions.

The Company has issued press releases disclosing partnerships with Pfizer, Merck & Co., Johnson & Johnson, and AstraZeneca, all citing the use of the company’s drug repositioning technology. Melior Discovery has also used its technology to discover its own drug candidates.

History

Melior Discovery was co-founded in 2005 by Dr. Andrew Reaume (President and CEO) and Dr. Michael Saporito (Vice President of Research).[1] Its investors include Cammeby’s Capital Group, VenturEast, Osage Ventures, Mid-Atlantic Angel Group, and BioAdvance.[2]

In March 2009, the Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a type 2 diabetes therapeutic candidate, MLR-1023.[3] In 2013, the company reported a licensing partnership with Bukwang Pharmaceutical Company LTD[4] and the initiation of clinical trials in March 2015.[5] In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects.[6]

External links

Notes and References

  1. Web site: NGP Europe - Drug Discovery - Productivity Crisis - Innovation Gap | GDS Publishing . Ngpharma.eu.com . 2011-05-26 . 2012-08-09 . dead . https://web.archive.org/web/20120303140619/http://www.ngpharma.eu.com/article/A-new-model-for-drug-discovery . 2012-03-03 .
  2. https://www.sec.gov/cgi-bin/browse-edgar?company=Melior+Discovery&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany EDGAR Search
  3. Web site: 2009-04-01 . The FDA also approved Melior discovery's IND application for the clinical development of its novel first-in-class kinase activator, MLR-1023, for the treatment of Type 2 diabetes. (New Drug Applications) .
  4. Melior Licenses Novel Diabetes Drug to Bukwang Pharmaceutical Co. . 4 December 2013 . December 4, 2013 . Business Wire.
  5. Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes . 3 March 2015 . March 3, 2015 . Business Wire.
  6. Web site: 2016-06-13 . Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study . 2019-12-11 . www.businesswire.com . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Melior Discovery".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.